Yusuf Erzin

Yusuf Erzin

Auto-generated profile, based on publicly available information

Yusuf Erzin

Department of Gastroenterology, İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
YEYusuf Erzin
Yusuf Erzin
HUHafize Uzun
Hafize Uzun
ACAykut Ferhat Celik
Aykut Ferhat Celik
SASeval Aydin
Seval Aydin
ADAhmet Dirican
Ahmet Dirican
HUHulya Uzunismail
Hulya Uzunismail
Homocysteine is a sulfur-containing amino acid formed during the demethylation of methionine and high levels of this amino acid is a known risk factor for both arterial and also venous thromboembolic complications. Deficiencies of cobalamin, folate, and pyridoxine may predispose subjects to hyperhomocysteinemia, a common phenomenon in inflammatory bowel disease (IBD) patients. The aim of this study was to identify the prevalence, risk factors of hyperhomocysteinemia and its correlation with prior thromboembolic events in an IBD cohort without past intestinal resections. In this prospective study, we studied the concentrations of homocysteine, cobalamin, folate, and pyridoxine in 105 consecutive patients with IBD, of whom 11 had a prior history of thromboembolic complications. Data regarding smoking habits, medication use, disease location, and severity were gathered and patients with past intestinal resections were excluded. Age-matched and sex-matched 85 healthy volunteers served as controls and multivariate regression analysis was performed to find out independent predictors of hyperhomocysteinemia. The mean age (+/-SD) in the IBD cohort was 38.69+/-12.13 years, and 51% were male. The mean age in the control group was 37.61+/-10.05 years, and 52% were male. Homocysteine concentrations in patients were higher [16.35 micromol/L (range 6.82 to 48.15) vs. 9.60 micromol/L (range 4.97 to 17.39), P=0.000] and hyperhomocysteinemia had a higher prevalence in patients than in the controls (56.2% vs. 4.7%, chi2=56.179, P=0.000), thus IBD significantly increased the risk of hyperhomocysteinemia [odds ratio=25.973 (95% confidence interval: 8.861-76.128)]. Homocysteine concentrations in patients with a history of thrombosis were not higher than those without a history of thrombosis [16.29 micromol/L (range 8.45 to 34.75) vs. 16.36 micromol/L (range 6.82 to 48.15), not significant]. Hyperhomocysteinemia was found in 54.5% of patients with thrombosis and 56.4% of patients without thrombosis (not significant). On stepwise regression analysis, plasma cobalamin level, albumin concentration, erythrocyte sedimentation rate, and platelet count were found to be independent predictors of elevated homocysteine levels. IBD patients have a higher prevalence of hyperhomocysteinemia than do healthy controls and elevated homocysteine levels are independently associated with lower serum cobalamin, albumin levels and elevated erythrocyte sedimentation rate, and platelet count. There is no correlation between hyperhomocysteinemia and a history of prior thromboembolic events.

1 April 2014 in Hepatobiliary & Pancreatic Diseases International
Verified
Journal Article
Closed access
GSGurhan Sisman
Gurhan Sisman
YEYusuf Erzin
Yusuf Erzin
IHIbrahim Hatemi
Ibrahim Hatemi
ECErkan Caglar
Erkan Caglar
SBSalih Boga
Salih Boga
HSHakan Senturk
Hakan Senturk

15 June 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
FAFiliz Akyuz
Filiz Akyuz
AÇAltay Çelebi
Altay Çelebi
İDİbrahim Doğan
İbrahim Doğan
YEYusuf Erzin
Yusuf Erzin
TKTaylan Kav
Taylan Kav
SKSabahattin Kaymakoğlu
Sabahattin Kaymakoğlu
Functional gastrointestinal system disorders are common problems in practice. The most common symptoms are abdominal pain, gas, bloating, diarrhea, constipation, and a mixture of these, and similar symptoms can be seen in conditions such as inflammatory bowel disease, colorectal cancer, and celiac disease depending on the age of the patient, indicating the importance of differential diagnosis. The importance of patient management is shown by making a symptom-based diagnosis and making cost-effective, that is, limited advanced examinations. The pathophysiology of irritable bowel syndrome (IBS) is multifactorial, and stress is one of the leading triggers of IBS symptoms. Therefore, terminology will change to gut–brain interaction disorders in the future, and the patient–physician relationship has a special place in the treatment of functional bowel disorder. Dietary recommendation and medical treatment in IBS should be determined according to the predominant symptom and symptom severity. In addition to diet, some lifestyle changes can also be helpful in reducing IBS symptoms. Antispasmodics and antidepressants are not fast-acting. These drugs should be used for at least 2-4 weeks to see the efficacy of treatment. Drugs should be used according to the standard recommended duration and dose in intermittent treatments. Cite this article as: Akyüz F, Çelebi A, Doğan İ, et al. Functional bowel disorder management in routine practice with tips for hot topics: Expert opinion review. Turk J Gastroenterol. 2024;35(6):423-439.

1 September 1997 in Leukemia Research
Verified
Journal Article
Closed access
BFBurhan Ferhanoğlu
Burhan Ferhanoğlu
YEYusuf Erzin
Yusuf Erzin
ZBZafer Başlar
Zafer Başlar
HTHilal Akl Nükhet Tüzüner
Hilal Akl Nükhet Tüzüner

15 January 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
FAFiliz Akyuz
Filiz Akyuz
OEOsman Ersoy
Osman Ersoy
YEYusuf Erzin
Yusuf Erzin
BÇBilger Çavuş
Bilger Çavuş
OBOguz Kagan Bakkaloglu
Oguz Kagan Bakkaloglu
CPCengiz Pata
Cengiz Pata
Capsule endoscopy, in clinical use since the 2000s, has disrupted the diagnosis of various small bowel diseases, especially obscuregastrointestinal bleeding. An overview of information on indications, contraindications, patient management, and patient preparationfor capsule endoscopy, which allows the evaluation of the entire gastrointestinal tract, will be helpful for both referrers and capsuleendoscopy. This review critically considers current evidence on the optimal clinical use of capsule endoscopy and addresses areas in the “gray zone.” Cite this article as: Akyüz F, Ersoy O, Erzin Y, et al. Small bowel video capsule endoscopy guidance in practice: Expert opinion report. Turk J Gastroenterol. 2023;34(S1):S2-S19.

16 March 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
RORana Berru Ozince
Rana Berru Ozince
TATumay Ak
Tumay Ak
YEYusuf Ziya Erzin
Yusuf Ziya Erzin
MMMelike Melikoglu
Melike Melikoglu
ESEmire Seyahi
Emire Seyahi
Objectives: Secukinumab (SEC) is an effective and widely used drug in psoriatic disease and axial spondyloarthritis. However, SEC has been found to be associated with inflammatory conditions and vasculitis. These inflammatory adverse effects may complicate the treatment of underlying disease, and clinicians may experience difficulties in recognizing and managing this unusual condition.Case Report: A man aged 56 years with psoriatic disease refractory to conventional disease‐modifying antirheumatic drugs was given adalimumab for 6 weeks, then switched to SEC when his psoriatic lesions were exacerbated. After 3 weeks of SEC treatment, he developed systemic features of IgA vasculitis while his skin lesions and arthritis persisted.Conclusions: Although SEC‐related inflammatory adverse events, including vasculitis, are rarely encountered in clinical practice, it is essential to recognize them because they can be mistaken as a component of the underlying inflammatory disease. In addition, the dramatic improvement in many cases after the cessation of SEC underlines the importance of making an accurate diagnosis. Pathogenetically, these adverse events are likely to be paradoxical reactions, except for SEC‐induced inflammatory bowel diseases. However, in many aspects, their pathogenesis is controversial and needs clarification.